health
Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal
Daiichi Sankyo and Merck & Co. have withdrawn an antibody-drug conjugate (ADC) filing after the FDA said they lacked the data for accelerated approval in a lung cancer population.
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
Moody? Aggressive? You could have ‘irritable male syndrome’
New York Post
Ozempic and Wegovy linked to brain health risks from caloric cuts
Fox News
After 20 Miscarriages, Mom Celebrates Son’s First Birthday: ‘I Couldn’t Give Up’ (Exclusive)
Yahoo
5 Georgia siblings diagnosed with measles
WSB-TV
People Who Drink Their Own Pee Are Obsessed With AI, Using It to Reassure Themselves That It's a Miraculous Cure-All
Futurism